stat+: pharmalittle: we’re reading about glp-1s becoming lifestyle drugs, a setback for merck and daiichi, and more

⚠️ Content Notice

This story relates to health or medical topics. HeadlineSift's AI-generated summaries are for informational purposes only and do not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare professional for medical decisions.